139 related articles for article (PubMed ID: 37982383)
1. Failure of the dual orexin receptor antagonist suvorexant to engender drug discrimination in rats.
Steiner MA; Toeroek-Schafroth M; Dacome L; Tessari M
J Psychopharmacol; 2023 Dec; 37(12):1261-1264. PubMed ID: 37982383
[TBL] [Abstract][Full Text] [Related]
2. Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant.
Born S; Gauvin DV; Mukherjee S; Briscoe R
Regul Toxicol Pharmacol; 2017 Jun; 86():181-192. PubMed ID: 28279667
[TBL] [Abstract][Full Text] [Related]
3. Is schedule IV suvorexant an appropriate reference drug of abuse to use in preclinical abuse liability testing in the rat?
Teuns GBA; Tessari M
Regul Toxicol Pharmacol; 2024 Mar; 148():105570. PubMed ID: 38286304
[TBL] [Abstract][Full Text] [Related]
4. Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem.
Ufer M; Kelsh D; Schoedel KA; Dingemanse J
Sleep; 2022 Mar; 45(3):. PubMed ID: 34480579
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.
Schoedel KA; Sun H; Sellers EM; Faulknor J; Levy-Cooperman N; Li X; Kennedy WP; Cha JH; Lewis NM; Liu W; Bondiskey P; McCrea JB; Panebianco DL; Troyer MD; Wagner JA
J Clin Psychopharmacol; 2016 Aug; 36(4):314-23. PubMed ID: 27253658
[TBL] [Abstract][Full Text] [Related]
6. Suvorexant, an orexin/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine.
Gentile TA; Simmons SJ; Barker DJ; Shaw JK; España RA; Muschamp JW
Addict Biol; 2018 Jan; 23(1):247-255. PubMed ID: 28419646
[TBL] [Abstract][Full Text] [Related]
7. Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure-Activity Relationships, and Sleep-Promoting Properties in Rats.
Brotschi C; Roch C; Gatfield J; Treiber A; Williams JT; Sifferlen T; Heidmann B; Jenck F; Bolli MH; Boss C
ChemMedChem; 2019 Jul; 14(13):1257-1270. PubMed ID: 31066976
[TBL] [Abstract][Full Text] [Related]
8. Can the Orexin Antagonist Suvorexant Preserve the Ability to Awaken to Auditory Stimuli While Improving Sleep?
Drake CL; Kalmbach DA; Cheng P; Roth T; Tran KM; Cuamatzi-Castelan A; Atkinson R; Singh M; Tonnu CV; Fellman-Couture C
J Clin Sleep Med; 2019 Sep; 15(9):1285-1291. PubMed ID: 31538599
[TBL] [Abstract][Full Text] [Related]
9. From Oxadiazole to Triazole Analogues: Optimization toward a Dual Orexin Receptor Antagonist with Improved in vivo Efficacy in Dogs.
Brotschi C; Bolli MH; Gatfield J; Heidmann B; Jenck F; Roch C; Sifferlen T; Treiber A; Williams JT; Boss C
ChemMedChem; 2020 Mar; 15(5):430-448. PubMed ID: 31945272
[TBL] [Abstract][Full Text] [Related]
10. Effects of Suvorexant, a Dual Orexin/Hypocretin Receptor Antagonist, on Impulsive Behavior Associated with Cocaine.
Gentile TA; Simmons SJ; Watson MN; Connelly KL; Brailoiu E; Zhang Y; Muschamp JW
Neuropsychopharmacology; 2018 Apr; 43(5):1001-1009. PubMed ID: 28741623
[TBL] [Abstract][Full Text] [Related]
11. Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects.
Uemura N; McCrea J; Sun H; Donikyan M; Zammit G; Liu R; Louridas B; Marsilio S; Lines C; Troyer MD; Wagner J
J Clin Pharmacol; 2015 Oct; 55(10):1093-100. PubMed ID: 25903940
[TBL] [Abstract][Full Text] [Related]
12. Non-selective orexin-receptor antagonist attenuates stress-re-stress-induced core PTSD-like symptoms in rats: Behavioural and neurochemical analyses.
Prajapati SK; Krishnamurthy S
Behav Brain Res; 2021 Feb; 399():113015. PubMed ID: 33212086
[TBL] [Abstract][Full Text] [Related]
13. Nonclinical evaluation of abuse liability of the dual orexin receptor antagonist lemborexant.
Asakura S; Shiotani M; Gauvin DV; Fujiwara A; Ueno T; Bower N; Beuckmann CT; Moline M
Regul Toxicol Pharmacol; 2021 Dec; 127():105053. PubMed ID: 34619288
[TBL] [Abstract][Full Text] [Related]
14. Abuse potential assessment of the dual orexin receptor antagonist daridorexant in rats.
Steiner MA; Toeroek-Schafroth M; Giusepponi ME; Dacome L; Tessari M
J Psychopharmacol; 2023 Dec; 37(12):1249-1260. PubMed ID: 38059356
[TBL] [Abstract][Full Text] [Related]
15. Role of hypocretin/orexin receptor blockade on drug-taking and ultrasonic vocalizations (USVs) associated with low-effort self-administration of cathinone-derived 3,4-methylenedioxypyrovalerone (MDPV) in rats.
Simmons SJ; Martorana R; Philogene-Khalid H; Tran FH; Gentile TA; Xu X; Su S; Rawls SM; Muschamp JW
Psychopharmacology (Berl); 2017 Nov; 234(21):3207-3215. PubMed ID: 28786030
[TBL] [Abstract][Full Text] [Related]
16. Suvorexant: first global approval.
Yang LP
Drugs; 2014 Oct; 74(15):1817-22. PubMed ID: 25227290
[TBL] [Abstract][Full Text] [Related]
17. Suvorexant: scientifically interesting, utility uncertain.
Keks NA; Hope J; Keogh S
Australas Psychiatry; 2017 Dec; 25(6):622-624. PubMed ID: 28994603
[TBL] [Abstract][Full Text] [Related]
18. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.
Patel KV; Aspesi AV; Evoy KE
Ann Pharmacother; 2015 Apr; 49(4):477-83. PubMed ID: 25667197
[TBL] [Abstract][Full Text] [Related]
19. Suvorexant maintenance enhances the reinforcing but not subjective and physiological effects of intravenous cocaine in humans.
Stoops WW; Strickland JC; Hatton KW; Hays LR; Rayapati AO; Lile JA; Rush CR
Pharmacol Biochem Behav; 2022 Oct; 220():173466. PubMed ID: 36152876
[TBL] [Abstract][Full Text] [Related]
20. Suvorexant as an orexin antagonist may regulate serum glucose levels in psychiatric patients with insomnia.
Nakamura M; Nagamine T
Psychiatry Clin Neurosci; 2017 Dec; 71(12):844. PubMed ID: 28945327
[No Abstract] [Full Text] [Related]
[Next] [New Search]
